Tian Mao-Lu, Hu Ying, Yuan Jing, Zha Yan
Department of Nephrology, Institute of Nephritic and Urinary Disease, Guizhou Provincial People's Hospital, Guiyang, China.
J Cardiovasc Pharmacol. 2015 Feb;65(2):130-6. doi: 10.1097/FJC.0000000000000169.
Urinary alkalinization with sodium bicarbonate infusion can theoretically protect against the mechanisms of acute kidney injury (AKI). Controversy exists regarding whether sodium bicarbonate infusion can reduce the incidence of AKI from cardiac surgery. A meta-analysis was conducted to show the efficacy and safety of perioperative sodium bicarbonate use for preventing AKI in patients undergoing cardiac surgery.
PubMed, CBM, EMBASE, CENTRAL, and Cochrane renal group specialized register were searched for pertinent studies.
Randomized controlled trails and prospective observational cohort studies that compared sodium bicarbonate with sodium chloride or blank control in cardiac surgery with cardiopulmonary bypass were included. Exclusion criteria were duplicate publications, nonadult studies, oral administration of sodium bicarbonate, retrospective analyses, and studies with small sample size (n < 50) or with no data on AKI.
Study end points, study design, population, operation information, and sodium bicarbonate doses were extracted.
Data from 1673 patients in 5 randomized trials and 1 prospective observational cohort study were analyzed. The analysis showed that sodium bicarbonate did not reduce the incidence of postoperative AKI and the need for renal replacement therapy. Postoperative ventilation time, hospital length of stay, hospital death, and mortality within 90 days had no statistical difference between 2 groups. Time in intensive care unit was even slightly longer in the experimental group.
Urinary alkalinization using sodium bicarbonate infusion failed to reduce the incidence rate of AKI or other outcomes in patients undergoing cardiac surgery. This intervention might even prolong intensive care unit stay.
输注碳酸氢钠使尿液碱化理论上可预防急性肾损伤(AKI)的发生机制。关于输注碳酸氢钠是否能降低心脏手术相关AKI的发生率存在争议。本荟萃分析旨在阐明围手术期使用碳酸氢钠预防心脏手术患者发生AKI的有效性和安全性。
检索了PubMed、中国生物医学文献数据库(CBM)、荷兰医学文摘数据库(EMBASE)、考克兰系统评价中心数据库(CENTRAL)以及考克兰肾脏组专业注册库,以查找相关研究。
纳入在心脏手术体外循环期间将碳酸氢钠与氯化钠或空白对照进行比较的随机对照试验和前瞻性观察性队列研究。排除标准为重复发表的文献、非成人研究、碳酸氢钠口服给药、回顾性分析以及样本量小(n < 50)或无AKI数据的研究。
提取研究终点、研究设计、人群、手术信息以及碳酸氢钠剂量。
分析了5项随机试验和1项前瞻性观察性队列研究中1673例患者的数据。分析表明,碳酸氢钠并未降低术后AKI的发生率以及肾脏替代治疗的需求。两组术后机械通气时间、住院时间、住院死亡率以及90天内死亡率无统计学差异。实验组在重症监护病房的时间甚至略长。
输注碳酸氢钠使尿液碱化未能降低心脏手术患者AKI的发生率或其他结局。这种干预甚至可能延长重症监护病房住院时间。